Molecular biology and pathology of lymphangiogenesis

Annual Review of Pathology: Mechanisms of Disease

Volumn 3, Issue , 2008, Pages 367-397

  Karpanen, Terhi ^a   Alitalo, Kari ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Inflammation; Lymphatic vascular development; Lymphatic vessel; Lymphedema; Tumor metastasis

Indexed keywords

ANGIOPOIETIN; CELL MARKER; EPHRIN B2; INTEGRIN; NEUROPILIN 2; PODOPLANIN; PROTEIN KINASE SYK; PROTEIN LYVE 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR PROX 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

BREAST CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHYLOUS ASCITES; ENDOTHELIUM CELL; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; INFLAMMATION; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIECTASIS; LYMPHANGIOGENESIS; LYMPHANGIOLEIOMYOMATOSIS; LYMPHEDEMA; METASTASIS; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; ENDOTHELIUM, LYMPHATIC; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; LYMPHEDEMA; MICE; MODELS, ANIMAL; MOLECULAR BIOLOGY; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 41749093830     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev.pathmechdis.3.121806.151515     Document Type: Review

References (152)

1. Jeltsch M, Tammela T, Alitalo K, Wilting J. 2003. Genesis and pathogenesis of lymphatic vessels. Cell Tissue Res. 314:69-84
2. Oliver G, Alitalo K. 2005. The lymphatic vasculature: recent progress and paradigms. Annu. Rev. Cell Dev. Biol. 21:457-83
3. Sabin FR. 1909. The lymphatic system in human embryos, with a consideration of the morphology of the system as a whole. Am. J. Anat. 9:43-91
4. Oliver G. 2004. Lymphatic vasculature development. Nat. Rev. Immunol. 4:35-45
5. Huntington GS, McClure CFW. 1908. The anatomy and development of the jugular lymph sac in the domestic cat (Felis domestica). Anat. Rec. 2:1-19
6. Ny A, Koch M, Schneider M, Neven E, Tong RT, et al. 2005. A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat. Med. 11:998-1004
7. Wilting J, Aref Y, Huang R, Tomarev SI, Schweigerer L, et al. 2006. Dual origin of avian lymphatics. Dev. Biol. 292:165-73
8. Kerjaschki D, Huttary N, Raab I, Regele H, Bojarski-Nagy K, et al. 2006. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat. Med. 12:230-34
9. Maruyama K, Ii M, Cursiefen C, Jackson DG, Keino H, et al. 2005. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin. Invest. 115:2363-72
10. Sebzda E, Hibbard C, Sweeney S, Abtahian F, Bezman N, et al. 2006. Syk and Slp-76 mutant mice reveal a cell-autonomous hematopoietic cell contribution to vascular development. Dev. Cell 11:349-61
11. He Y, Rajantie I, Ilmonen M, Mäkinen T, Karkkainen MJ, et al. 2004. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res. 64:3737-40
12. Achen MG, Stacker SA. 2006. Tumor lymphangiogenesis and metastatic spread-new players begin to emerge. Int. J. Cancer 119:1755-60
13. Cueni LN, Detmar M. 2006. New insights into the molecular control of the lymphatic vascular system and its role in disease. J. Invest. Dermatol. 126:2167-77
14. Jackson DG. 2004. Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. APMIS 112:526-38
15. Mäkinen T, Adams RH, Bailey J, Lu Q, Ziemiecki A, et al. 2005. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev. 19:397-410
16. Gale NW, Prevo R, Espinosa J, Ferguson DJ, Dominguez MG, et al. 2007. Normal lymphatic development and function in mice deficient for the lymphatic hyaluronan receptor LYVE-1. Mol. Cell. Biol. 27:595-604
17. Wigle JT, Oliver G. 1999. Prox1 function is required for the development of the murine lymphatic system. Cell 98:769-78
18. Wigle JT, Harvey N, Detmar M, Lagutina I, Grosveld G, et al. 2002. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J. 21:1505-13
19. Hong YK, Harvey N, Noh YH, Schacht V, Hirakawa S, et al. 2002. Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev. Dyn. 225:351-57
20. Petrova TV, Mäkinen T, Makela TP, Saarela J, Virtanen I, et al. 2002. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J. 21:4593-99
21. Backhed F, Crawford PA, O'Donnell D, Gordon JI. 2007. Postnatal lymphatic partitioning from the blood vasculature in the small intestine requires fasting-induced adipose factor. Proc. Natl. Acad. Sci. USA 104:606-11
22. Harvey NL, Srinivasan RS, Dillard ME, Johnson NC, Witte MH, et al. 2005. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nat. Genet. 37:1072-81
23. Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, et al. 1998. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282:946-49
24. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VWM, Fang G-H, et al. 1995. Expression of the fms-like tyrosine kinase FLT4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl Acad. Sci. USA 92:3566-70
25. Mäkinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, et al. 2001. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 7:199-205
26. Karpanen T, Wirzenius M, Mäkinen T, Veikkola T, Haisma H, et al. 2006. Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation. Am. J. Pathol. 169:708-18
27. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, et al. 2000. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat. Genet. 25:153-59
28. Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M. 2000. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am. J. Hunt. Genet. 67:295-301
29. Karkkainen MJ, Saaristo A, Jussila L, Karila KA, Lawrence EC, et al. 2001. A model for gene therapy of human hereditary lymphedema. Proc. Natl Acad. Sci. USA 98:12677-82
30. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, et al. 1997. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276:1423-25
31. Veikkola T, Jussila L, Mäkinen T, Karpanen T, Jeltsch M, et al. 2001. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 20:1223-31
32. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, et al. 2004. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 5:74-80
33. Baldwin ME, Halford MM, Roufail S, Williams RA, Hibbs ML, et al. 2005. Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol. Cell. Biol. 25:2441-49
34. Ober EA, Olofsson B, Mäkinen T, Jin SW, Shoji W, et al. 2004. Vegfc is required for vascular development and endoderm morphogenesis in zebrafish. EMBO Rep. 5:78-84
35. Witzenbichler B, Asahara T, Murohara T, Silver M, Spyridopoulos I, et al. 1998. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am. J. Pathol. 153:381-94
36. Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, et al. 2003. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ. Res. 92:1098-106
37. Mäkinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, et al. 2001. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 20:4762-73
38. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, et al. 1997. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16:3898-911
39. Stacker SA, Stenvers K, Caesar C, Vitali A, Domagala T, et al. 1999. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J. Biol. Chem. 274:32127-36
40. Saaristo A, Veikkola T, Tammela T, Enholm B, Karkkainen MJ, et al. 2002. Lymphangiogenic gene therapy with minimal blood vascular side effects. J. Exp. Med. 196:719-30
41. Goldman J, Rutkowski JM, Shields JD, Pasquier MC, Cui Y, et al. 2007. Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis. FASEB J. 21:1003-12
42. Wirzenius M, Tammela T, Uutela M, He Y, Odorisio T, et al. 2007. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J. Exp. Med. 204:1431-40
43. Dixelius J, Mäkinen T, Wirzenius M, Karkkainen MJ, Wernstedt C, et al. 2003. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J. Biol. Chem. 278:40973-79
44. Joukov V, Kumar V, Sorsa T, Arighi E, Weich H, et al. 1998. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J. Biol. Chem. 273:6599-602
45. Karpanen T, Heckman CA, Keskitalo S, Jeltsch M, Ollila H, et al. 2006. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J. 20:1462-72
46. Yuan L, Moyon D, Pardanaud L, Breant C, Karkkainen MJ, et al. 2002. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129:4797-806
47. Wang JF, Zhang X-F, Groopman JE. 2001. Stimulation of β1 integrin induces tyrosine phosphorylation of VEGF receptor-3 and modulates cell migration. J. Biol. Chem. 276:41950-57
48. Zhang X, Groopman JE, Wang JF. 2005. Extracellular matrix regulates endothelial functions through interaction of VEGFR-3 and integrin α5β1. J. Cell Physiol. 202:205-14
49. Huang XZ, Wu JF, Ferrando R, Lee JH, Wang YL, et al. 2000. Fatal bilateral chylothorax in mice lacking the integrin α9β1. Mol. Cell. Biol. 20:5208-15
50. Vlahakis NE, Young BA, Atakilit A, Sheppard D. 2005. The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin α9β1. J. Biol. Chem. 280:4544-52
51. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, et al. 2002. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev. Cell 3:411-23
52. Morisada T, Oike Y, Yamada Y, Urano T, Akao M, et al. 2005. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood 105:4649-56
53. Tammela T, Saaristo A, Lohela M, Morisada T, Tornberg J, et al. 2005. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 105:4642-48
54. Karpanen T, Mäkinen T. 2006. Regulation of lymphangiogenesis-from cell fate determination to vessel remodeling. Exp. Cell Res. 312:575-83
55. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, et al. 2005. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 65:4739-46
56. Foo SS, Turner CJ, Adams S, Compagni A, Aubyn D, et al. 2006. Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell 124:161-73
57. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, et al. 1999. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am. J. Pathol. 154:385-94
58. Schacht V, Ramirez MI, Hong YK, Hirakawa S, Feng D, et al. 2003. T1α/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J. 22:3546-56
59. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. 2006. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9:261-72
60. Dagenais SL, Hartsough RL, Erickson RP, Witte MH, Butler MG, et al. 2004. Foxc2 is expressed in developing lymphatic vessels and other tissues associated with lymphedemadistichiasis syndrome. Gene Expr. Patterns 4:611-19
61. Petrova TV, Karpanen T, Norrmen C, Mellor R, Tamakoshi T, et al. 2004. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat. Med. 10:974-81
62. Aalami OO, Allen DB, Organ CH Jr. 2000. Chylous ascites: a collective review. Surgery 128:761-78
63. Abtahian F, Guerriero A, Sebzda E, Lu MM, Zhou R, et al. 2003. Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science 299:247-51
64. Stacker SA, Baldwin ME, Achen MG. 2002. The role of tumor lymphangiogenesis in metastatic spread. FASEB J. 16:922-34
65. Alitalo K, Carmeliet P. 2002. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1:219-27
66. Pepper MS, Tille JC, Nisato R, Skobe M. 2003. Lymphangiogenesis and tumor metastasis. Cell Tissue Res. 314:167-77
67. Beasley NJ, Prevo R, Banerji S, Leek RD, Moore J, et al. 2002. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res. 62:1315-20
68. Maula SM, Luukkaa M, Grenman R, Jackson D, Jalkanen S, et al. 2003. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res. 63:1920-26
69. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, et al. 2002. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296:1883-86
70. Wong SY, Haack H, Crowley D, Barry M, Bronson RT, et al. 2005. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res. 65:9789-98
71. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. 2002. Lymphangiogenesis and cancer metastasis. Nat. Rev. Cancer 2:573-83
72. He Y, Karpanen T, Alitalo K. 2004. Role of lymphangiogenic factors in tumor metastasis. Biochim. Biophys. Acta 1654:3-12
73. Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, et al. 1999. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am. J. Pathol. 154:1381-90
74. Kubo H, Fujiwara T, Jussila L, Hashi H, Ogawa M, et al. 2000. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood 96:546-53
75. Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B, et al. 2007. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res. 67:593-99
76. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, et al. 2001. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7:192-98
77. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, et al. 2001. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7:186-91
78. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, et al. 2001. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20:672-82
79. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, et al. 2001. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 61:1786-90
80. Yanai Y, Furuhata T, Kimura Y, Yamaguchi K, Yasoshima T, et al. 2001. Vascular endothelial growth factor C promotes human gastric carcinoma lymph node metastasis in react. J. Exp. Clin. Cancer Res. 20:419-28
81. Mattila MM, Ruohola JK, Karpanen T, Jackson DG, Alitalo K, et al. 2002. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int. J. Cancer 98:946-51
82. Kawakami M, Yanai Y, Hata F, Hirata K. 2005. Vascular endothelial growth factor C promotes lymph node metastasis in a rectal cancer orthotopic model. Surg. Today 35:131-38
83. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, et al. 2002. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl. Cancer Inst. 94:819-25
84. Krishnan J, Kirkin V, Steffen A, Hegen M, Weih D, et al. 2003. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res. 63:713-22
85. Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, et al. 2005. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res. 65:6901-9
86. Shimizu K, Kubo H, Yamaguchi K, Kawashima K, Ueda Y, et al. 2004. Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci. 95:328-33
87. Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, et al. 2006. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 66:2650-57
88. Chen Z, Varney ML, Backora MW, Cowan K, Solheim JC, et al. 2005. Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res. 65:9004-11
89. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. 2002. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat. Med. 8:751-55
90. Fiedler U, Christian S, Koidl S, Kerjaschki D, Emmett MS, et al. 2006. The sialomucin CD34 is a marker of lymphatic endothelial cells in human tumors. Am. J. Pathol. 168:1045-53
91. Skobe M, Hamberg LM, Hawighorst T, Schirner M, Wolf GL, et al. 2001. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am. J. Pathol. 159:893-903
92. Alitalo K, Tammela T, Petrova TV. 2005. Lymphangiogenesis in development and human disease. Nature 438:946-53
93. Hoshida T, Isaka N, Hagendoorn J, di Tomaso E, Chen YL, et al. 2006. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res. 66:8065-75
94. Shields JD, Emmett MS, Dunn DB, Joory KD, Sage LM, et al. 2006. Chemokine-mediated migration of melanoma cells towards lymphatics: a mechanism contributing to metastasis. Oncogene 26:2997-3005
95. Harrell MI, Iritani BM, Ruddell A. 2007. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am. J. Pathol. 170:774-86
96. Qian CN, Berghuis B, Tsarfaty G, Bruch M, Kort EJ, et al. 2006. Preparing the "soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res. 66:10365-76
97. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, et al. 2005. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J. Exp. Med. 201:1089-99
98. Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, et al. 2007. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 109:1010-17
99. Christofori G. 2006. New signals from the invasive front. Nature 441:444-50
100. Ruoslahti E. 2004. Vascular zip codes in angiogenesis and metastasis. Biochem. Soc. Trans. 32:397-402
101. Muller A, Homey B, Soto H, Ge N, Catron D, et al. 2001. Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56
102. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, et al. 1998. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and Chemotaxis of naive T lymphocytes. Proc. Natl. Acad. Sci. USA 95:258-63
103. Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST. 2001. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J. Natl. Cancer Inst. 93:1638-43
104. Zlotnik A. 2004. Chemokines in neoplastic progression. Semin. Cancer Biol. 14:181-85
105. Rockson SG. 2001. Lymphedema. Am. J. Med. 110:288-95
106. Yla-Herttuala S, Alitalo K. 2003. Gene transfer as a tool to induce therapeutic vascular growth. Nat. Med. 9:694-701
107. Saaristo A, Tammela T, Timonen J, Yla-Herttuala S, Tukiainen E, et al. 2004. Vascular endothelial growth factor-C gene therapy restores lymphatic flow across incision wounds. FASEB J. 18:1707-9
108. Saaristo A, Tammela T, Farkkila A, Karkkainen M, Suominen E, et al. 2006. Vascular endothelial growth factor-C accelerates diabetic wound healing. Am. J. Pathol. 169:1080-87
109. Brice G, Child AH, Evans A, Bell R, Mansour S, et al. 2005. Milroy disease and the VEGFR-3 mutation phenotype. J. Med. Genet. 42:98-102
110. Holberg CJ, Erickson RP, Bernas MJ, Witte MH, Fultz KE, et al. 2001. Segregation analyses and a genome-wide linkage search confirm genetic heterogeneity and suggest oligogenic inheritance in some Milroy congenital primary lymphedema families. Am. J. Med. Genet. 98:303-12
111. Finegold DN, Kimak MA, Lawrence EC, Levinson KL, Cherniske EM, et al. 2001. Truncating mutations in FOXC2 cause multiple lymphedema syndromes. Hum. Mol. Genet. 10:1185-89
112. Ferrell RE. 2002. Research perspectives in inherited lymphatic disease. Annu. NY Acad. Sci. 979:39-51
113. Sholto-Douglas-Vernon C, Bell R, Brice G, Mansour S, Sarfarazi M, et al. 2005. Lymphoedema-distichiasis and FOXC2: unreported mutations, de novo mutation estimate, families without coding mutations. Haw. Genet. 117:238-42
114. Fang J, Dagenais SL, Erickson RP, Arlt MF, Glynn MW, et al. 2000. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am. J. Hum. Genet. 67:1382-88
115. Yildirim-Toruner C, Subramanian K, El Manjra L, Chen E, Goldstein S, et al. 2004. A novel frameshift mutation of FOXC2 gene in a family with hereditary lymphedemadistichiasis syndrome associated with renal disease and diabetes mellitus. Am. J. Med. Genet. A 131:281-86
116. Brice G, Mansour S, Bell R, Collin JR, Child AH, et al. 2002. Analysis of the pheno-typic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. J. Med. Genet. 39:478-83
117. Irrthum A, Devriendt K, Chitayat D, Matthijs G, Glade C, et al. 2003. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am. J. Hum. Genet. 72:1470-78
118. Bull LN, Roche E, Song EJ, Pedersen J, Knisely AS, et al. 2000. Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q. Am. J. Hum. Genet. 67:994-99
119. Zinn AR, Tonk VS, Chen Z, Flejter WL, Gardner HA, et al. 1998. Evidence for a Turner syndrome locus or loci at Xp11.2-p22.1. Am. J. Hum. Genet. 63:1757-66
120. Dreyer G, Noroes J, Figueredo-Silva J, Piessens WF. 2000. Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective. Parasitol. Today 16:544-48
121. Jussila L, Valtola R, Partanen TA, Salven P, Heikkila P, et al. 1998. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 58:1599-604
122. Zhang X, Wang JF, Chandran B, Persaud K, Pytowski B, et al. 2005. Kaposi's sarcoma-associated herpesvirus activation of vascular endothelial growth factor receptor 3 alters endothelial function and enhances infection. J. Biol. Chem. 280:26216-24
123. Hong YK, Foreman K, Shin JW, Hirakawa S, Curry CL, et al. 2004. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat. Genet. 36:683-85
124. Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, et al. 2004. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat. Genet. 36:687-93
125. Juvet SC, McCormack FX, Kwiatkowski DJ, Downey GP. 2006. Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am. J. Respir. Cell Mol. Biol. 36:398-408
126. Kumasaka T, Seyama K, Mitani K, Sato T, Souma S, et al. 2004. Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis. Am. J. Surg. Pathol. 28:1007-16
127. Seyama K, Kumasaka T, Souma S, Sato T, Kurihara M, et al. 2006. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat. Res. Biol. 4:143-52
128. Kumasaka T, Seyama K, Mitani K, Souma S, Kashiwagi S, et al. 2005. Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am. J. Surg. Pathol. 29:1356-66
129. Hagendoorn J, Padera TP, Yock TI, Nielsen GP, di Tomaso E, et al. 2006. Platelet-derived growth factor receptor-β in Gorham's disease. Nat. Clin. Pract. Oncol. 3:693-97
130. Ohl L, Mohaupt M, Czeloth N, Hintzen G, Kiafard Z, et al. 2004. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 21:279-88
131. Irjala H, Johansson EL, Grenman R, Alanen K, Salmi M, et al. 2001. Mannose receptor is a novel ligand for L-selectin and mediates lymphocyte binding to lymphatic endothelium. J. Exp. Med. 194:1033-42
132. Salmi M, Koskinen K, Henttinen T, Elima K, Jalkanen S. 2004. CLEVER-1 mediates lymphocyte transmigration through vascular and lymphatic endothelium. Blood 104:3849-57
133. Ristimaki A, Narko K, Enholm B, Joukov V, Alitalo K. 1998. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J. Biol. Chem. 273:8413-18
134. Chilov D, Kukk E, Taira S, Jeltsch M, Kaukonen J, et al. 1997. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J. Biol. Chem. 272:25176-83
135. Saban MR, Memet S, Jackson DG, Ash J, Roig AA, et al. 2004. Visualization of lymphatic vessels through NF-κB activity. Blood 104:3228-30
136. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, et al. 2004. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest. 113:1040-50
137. Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, et al. 2002. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol. 161:947-56
138. Kerjaschki D, Regele HM, Moosberger I, Nagy-Bojarski K, Watschinger B, et al. 2004. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J. Am. Soc. Nephrol. 15:603-12
139. Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, et al. 2005. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J. Clin. Invest. 115:247-57
140. Hamrah P, Chen L, Zhang Q, Dana MR. 2003. Novel expression of vascular endodielial growth factor receptor (VEGFR)-3 and VEGF-C on corneal dendritic cells. Am. J. Pathol. 163:57-68
141. Chen L, Hamrah P, Cursiefen C, Zhang Q, Pytowski B, et al. 2004. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat. Med. 10:813-15
142. Kajiya K, Detmar M. 2006. An important role of lymphatic vessels in the control of UVB-induced edema formation and inflammation. J. Invest. Dermatol. 126:919-21
143. Kunstfeld R, Hirakawa S, Hong YK, Schacht V, Lange-Asschenfeldt B, et al. 2004. Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 104:1048-57
144. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, et al. 2006. Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation. Nat. Med. 12:235-39
145. Kriederman BM, Myloyde TL, Witte MH, Dagenais SL, Witte CL, et al. 2003. FOXC2 haploinsufficient mice are a model for human autosomal dominant lymphedemadistichiasis syndrome. Hum. Mol. Genet. 12:1179-85
146. Ayadi A, Zheng H, Sobieszczuk P, Buchwalter G, Moerman P, et al. 2001. Net-targeted mutant mice develop a vascular phenotype and up-regulate egr-1. EMBO J. 20:5139-52
147. Fruman DA, Mauvais-Jarvis F, Pollard DA, Yballe CM, Brazil D, et al. 2000. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 a. Nat. Genet. 26:379-82
148. Pennisi D, Gardner J, Chambers D, Hosking B, Peters J, et al. 2000. Mutations in Sox18 underlie cardiovascular and hair follicle defects in ragged mice. Nat. Genet. 24:434-37
149. Gittenberger-De Groot AC, Van Den Akker NM, Bartelings MM, Webb S, Van Vugt JM, Haak MC. 2004. Abnormal lymphatic development in trisomy 16 mouse embryos precedes nuchal edema. Dev. Dyn. 230:378-84
150. Kuhnert F, Campagnolo L, Xiong JW, Lemons D, Fitch MJ, et al. 2005. Dosage-dependent requirement for mouse Vezf1 in vascular system development. Dev. Biol. 283:140-56
151. Kuchler AM, Gjini E, Peterson-Maduro J, Cancilla B, Wolburg H, Schulte-Merker S. 2006. Development of the zebrafish lymphatic system requires VEGFC signaling. Curr. Biol. 16:1244-48
152. Yaniv K, Isogai S, Castranova D, Dye L, Hitomi J, Weinstein BM. 2006. Live imaging of lymphatic development in the zebrafish. Nat. Med. 12:711-16